Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
Subscribe To Our Newsletter & Stay Updated
